Stock drops nearly 10% in premarket trading

  • Alpine Immune Sciences shares fell nearly 10% in premarket trading
  • The company priced its $150 million public offering
  • Shares were sold at $12.50 apiece, 12% below Monday’s closing price
  • Positive data from a drug candidate study boosted shares last week
  • Stock ended Monday’s session down 12% after announcement of public offering

Shares of Alpine Immune Sciences dropped nearly 10% in premarket trading following the pricing of the company’s $150 million public offering. The clinical-stage immunotherapy company is selling 12 million shares and pre-funded warrants at $12.50 apiece, which is nearly 12% below Monday’s closing price. Last week, the stock saw a significant increase of over 70% due to positive data from a study of its drug candidate. However, the stock ended Monday’s session down 12% after the company announced the public offering.

Factuality Level: 8
Factuality Justification: The article provides factual information about the pricing of Alpine Immune Sciences’ public offering and the decline in the company’s stock. It also mentions the positive data from a study of its drug candidate and the stock’s performance last week. The information is presented objectively without any bias or opinion.
Noise Level: 3
Noise Justification: The article provides relevant information about Alpine Immune Sciences’ public offering and the impact on its stock price. It also mentions the positive data from a study of its drug candidate. However, it lacks in-depth analysis, scientific rigor, and actionable insights.
Financial Relevance: Yes
Financial Markets Impacted: Shares of Alpine Immune Sciences
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to the financial topic of Alpine Immune Sciences’ public offering and its impact on the company’s stock price.
Public Companies: Alpine Immune Sciences (unknown)
Key People:

Reported publicly: www.marketwatch.com